ANALYSIS OF THE COURSE OF ACUTE CORONARY SYNDROME AFTER COVID-19

COVID-19 is a risk factor for the development of the acute coronary syndrome. There is no data in the literature on the terms and frequency of ACS development, and also its course after COVID-19.
The aim. To analyze the course of the acute coronary syndrome in patients after COVID-19 and to assess the role of instrumental and biochemical parameters in patients with this pathology.
Materials and methods. The study group consisted of 35 patients with acute coronary syndrome after COVID-19. The analysis of clinical, instrumental and laboratory data of patients was carried out upon admission to the hospital: anamnesis of life and illness, electro- and echocardiography, coronary angiography, values of highly sensitive troponin T and N-terminal fragment of the pro-brain natriuretic peptide. The obtained results were processed by static analysis methods.
The results. Analysis of the course of the acute coronary syndrome in patients after COVID-19 made it possible to draw the following conclusions; acute coronary syndrome developed in patients 2-8 weeks after mild COVID-19. The acute coronary syndrome was most often observed in men. The acute coronary syndrome was characterized by a Q-forming myocardial infarction, in 25 (68,6 %) patients single vascular damage of the coronary arteries was detected, in 10 (31,4 %) – multi-vascular damage of the coronary arteries; most often there was damage of the right coronary artery, anterior descending artery and combined damage of the anterior descending artery and right coronary artery. Coronary artery damage was accompanied by an increase in highly sensitive troponin T to an average of 335,0 ng/ml. Cardiomyocyte damage was associated with heart failure, as evidenced by the values of the N-terminal fragment of the pro-brain natriuretic peptide. 

1. Boytsov S. A. Influenza, novel coronavirus infection and cardiovascular disease. Kardiologicheskiy vestnik = Russian Cardiology Bulletin. 2021; 16 (1): 5–10 (in Russ).

2. Romanov Yu. A. SARS-CoV-2, Covid-19 and cardiovascular complications from the position of vascular endothelium. Kardiologicheskij Vestnik = Russian Cardiology Bulletin. 2022; 17 (1): 21–28 (in Russ).

3. Sabirov I. S., Murkamilov I. T., Fomin V. V. Clinical and pathogenetic aspects of damage to the cardiovascular system in a new coronavirus infection (COVID-19). The scientific heritage. 2020; (53-1 (53)): 10–20 (in Russ).

4. Petrova O. V., Shabanova G. R., Nikulina D. M., Shashin S. A., Tarasov D. G., Golubkina S. A. Method for predicting cardiovascular complications in patients with ischemic heart disease in combination with ischemic mitral insufficiency. Patent PF, no. 2712634, 2019 (in Russ).

5. Petrova O. V., Shabanova G. R., Nikulina D. M., Shashin S. A., Tarasov D. G., Golubkina S. A. Method for predicting cardiovascular complications in patients with ischemic heart disease in combination with postinfarction left ventricular aneurysm. Patent PF, no. 2712629, 2019 (in Russ).

6. Barragán A., Lacalzada J., de la Rosa A., De Vera AM., Duque A., Perera C., Lara A., Laynez I. Relationship between slightly elevated NT-proBNP and alterations in diastolic function detected by echocardiography in patients without structural heart disease. Int J Cardiol. 2008; 129 (3): 430–2. doi: 10.1016/j.igcard.2007.06.097.

7. Lang R. M., Badano L. P., Mor-Avi V., Afilalo J., Armstrong A., Ernande L., Flachskampf F. A., Foster E., Goldstein S. A., Kuznetsova T., Lancellotti P., Muraru D., Picard M. H., Rietzschel E. R., Rudski L., Spencer K. T., Tsang W., Voigh J. U. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Journal of the American Society of Echocardiography. 2015; 28 (1): 1–39e14. doi:10.1016/j.echo.2014.10.003.

8. Shreider E. V., Shakhnovitch R. M., Bosykh E. G., Ruda M. YA. Peculiarities of dynamics and prognostic value of NT-proBNP level in different variants of treatment of patients with acute coronary syndrome. Kardiologiia = Cardiology. 2010; 2: 15–20 (in Russ).

9. Petrova O. V., Tverdokhlebova D. K., Nikulina D. M., Tarasov D. G. Place of serological test-systems for detection of antibodies to SARS-CoV2 in emergency cardiac surgery. Meditsinskiy alfavit = Medicalalphabet. 2021; (13): 18–21 (in Russ).

10. Bergmark B. A., Mathenge N., Merlini P. A., Lawrence-Wright M. B., Giugliano R. P. Acute coronary syndromes. Lancet. 2022; 399 (10332): 1347–1358. doi: 10.1016/S0140-6736(21)02391-6.

11. Inciardi R. M., Lupi L., Zaccone G., Italia L., Raffo M., Tomasoni D., Cani D. S., Cerini M., Farina D., Gavazzi E., Maroldi R., Adamo M., Ammirati E., Sinagra G., Lombardi C. M., Metra M. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA cardiology. 2020; 5 (7): 819–824. doi:10.1001./jamacardio.2020.1096.

12. Zhao X. Y., Li J. X., Tang X. F., Xu J. J., Song Y., Jiang L., Chen J., Song L., Gao L. J., Gao Z., Qiao S. B., Yang Y. J., Gao R. L., Xu B., Yuan J. Q. Prognostic value of NT-proBNP in stable coronary artery disease in Chinese patients after percutaneous coronary intervention in the drug-eluting stent era. Biomedical and environmental sciences : BES. 2018; 31 (12): 859–866. doi: 10.3967/bes2018.117.

13. Radwan H., Selem A., Ghazal K. Value of N-terminal pro brain natriuretic peptide in predicting prognosis and severity of coronary artery disease in acute coronary syndrome. Journal of the Saudi Heart Association. 2014; 26 (4): 192–8. doi: 10.1016/j.jsha.2014.04.004.

14. Petrova O. V., Motreva A. P., Tarasov D. G. Preoperative of N-terminal pro-brain natriuretic in cardiosurgical patients. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2013; 8(3): 74–79 (in Russ).

15. Petrova O. V., Egorova T. G., Shabanova G. R., Brentsis Z. Yu. The dynamics of troponin T, fractions MB creatine phosphate kinase and myoglobin in patients with ischemic heart disease after coronary bypass crafting on the working. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2012; 7 (2): 83–86 (in Russ).

16. Neverova Yu. N., Tarasov R. S., Nagirnyak O. A. Main predictors of in-hospital adverse outcomes in non-ST elevation acute coronary syndrome patients with multiverse disease. Kardiovaskulyarnaya terapiya I profilaktika = Cardiovascular therapy and prevention. 2018; 17 (4): 19–25 (in Russ).

17. Arcari L., Luciani M., Cacciotti L., Musumeci M. B., Spuntarelli V., Pistella E., Martolini D., Manzo D., Pucci M., Marone C., Melandri S., Ansalone G., Santini C., Martelletti P., Volpe M., De Biase L. Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. Internal and emergency medicine. 2020; 15 (8): 1467–1476. doi:10.1007/s11739-020-02498-7.

18. de Falco R., Vargas M., Palma D., Savoia M., Miscioscia A., Pinchera B., Vano M., Servillo G., Gentile I., Fortunato G. B-Type Natriuretic Peptides and high-sensitive troponin I as COVID-19 survival factors: which one is the best performer. Journal of Clinical Medicine. 2021; 10 (12): 2726. doi: 10.3390/jcm10122726.

19. De Minchieli L., Ola O., Knott J. D., Akula A., Mehta R.A., Hodge D. O., Dworak M., Yang E. H., Gharacholou M., Singh G., Singh R., Gulati R., Jaffe A. S., Sandoval Y. High-Sensitivity Cardiac Troponin T for the Detection of Myocardial Injury and risk stratification in COVID-19. Clinical Chemistry. 2021; 67(8): 1080–1089. doi: 10.1093/clinchem/hvab062.

20. Garg P., Morris P., Fazlanie A. L, Vijayan S., Dancso B., Dastidar A. G, Plein S., Mueller C., Haaf P. Cardiac biomarkers of acute coronary syndrome : from history to high-sensitivity cardiac troponin. Internal and Emergency Medicine. 2017; 12 (2): 147–155. doi: 10.1007/s11739-017-1612-1.

21. Kivva V.N., Abramova T.N. Pathogenesis of heart failure. Astrakhanskiy meditsinskiy zhurnal = Astrakhan Medical Journal. 2019; 4 (1): 73–81 (in Russ).

22. Lippi G., Lavie C. J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID19) : Evidence from a meta-analysis. Progress in cardiovascular diseases. 2020; 63 (3): 390–391. doi: 10.1016/j.pcad.2020.03.001.

23. Perrone M. A., Spolaore F., Ammirabile M., Romeo F., Caciagli P., Ceriotti F., Bernardini S.The assessment of high sensitivity cardiac troponin in patients with COVID-19 : A multicenter study. International journal of cardiology. Heart & vasculature. 2021; 32: 100715. doi: 10.1016/j.ijcha.2021.100715.